AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
94 hedge funds and large institutions have $119M invested in AVEO Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 30 increasing their positions, 13 reducing their positions, and 25 closing their positions.
552% more call options, than puts
Call options by funds: $13.7M | Put options by funds: $2.1M
131% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 13
24% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 25
4% more funds holding
Funds holding: 90 → 94 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
31% less capital invested
Capital invested by funds: $173M → $119M (-$54.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$12.1M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$3.37M |
| 3 |
State Street
Boston,
Massachusetts
|
+$3.36M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$2.08M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$9.37M |
| 2 |
Millennium Management
New York
|
-$3.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.73M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$2.12M |
| 5 |
Goldman Sachs
New York
|
-$1.81M |
AVEO Hedge Fund Activity: Q2 2018 in Review
94 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q2 2018, worth a combined $119M — down 31% from $173M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new AVEO positions and 25 closed out — a net gain of 6 holders — while 30 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock, adding an estimated $12.1M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $9.37M sold.
- 94 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q2 2018, up from 90 in Q1 2018.
- Funds reported $119M of AVEO Pharmaceuticals, Inc. stock for Q2 2018, down 31% quarter-over-quarter.
- 31 funds opened new AVEO Pharmaceuticals, Inc. positions in Q2 2018 and 25 closed out, a net change of +6 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q2 2018 was BlackRock, an estimated $12.1M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q2 2018 was Avoro Capital Advisors, an estimated $9.37M sold.
Based on aggregated 13F filings for Q2 2018.